Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Novan to immediately receive $12 million of non-dilutive capitalLigand to receive milestones and tiered royalty for North America SB206 molluscum indicationPhase 3 molluscum trial to begin recruitment...
-
MORRISVILLE, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019...
-
$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line resultsPipeline...
-
Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint CommitteeSimultaneous clinical development progress for SB206 in Japan and US underwayNovan receives second installment of $4.5...
-
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
-
End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early MarchActive business development discussions ongoing around certain late-stage assets and broader dermatology platformDr....
-
Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer of Novan Dr. Carri Geer promoted to Senior Vice President and Chief Technology Officer Dr. Elizabeth...
-
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...
-
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05)Statistically significant reductions in molluscum lesions as early as Week...
-
MORRISVILLE, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan Stasko,...